1CM
LGND icon

1492 Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

1492 Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$391K Buy
1,958
+82
+4% +$16.2K 0.15% 91
2025
Q4 		$355K Hold
1,876
– – 0.14% 83
2025
Q3 		$332K Hold
1,876
– – 0.13% 84
2025
Q2 		$213K Buy
+1,876
New +$201K 0.1% 107
2019
Q2 		– Sell
-12,880
Closed -$1.01M – 93
2019
Q1 		$1.01M Sell
12,880
-1,266
-9% -$95.9K 0.86% 39
2018
Q4 		$1.2M Sell
14,146
-1,078
-7% -$115K 1.07% 29
2018
Q3 		$2.61M Sell
15,224
-104
-0.7% -$15.7K 1.7% 22
2018
Q2 		$1.98M Sell
15,328
-240
-2% -$26.8K 1.42% 28
2018
Q1 		$1.6M Hold
15,568
– – 1.23% 29
2017
Q4 		$1.33M Sell
15,568
-125
-0.8% -$10.8K 1.04% 31
2017
Q3 		$1.33M Sell
15,693
-48
-0.3% -$3.8K 1.18% 29
2017
Q2 		$1.19M Sell
15,741
-392
-2% -$27.4K 1.05% 31
2017
Q1 		$1.06M Hold
16,133
– – 0.83% 38
2016
Q4 		$1.02M Sell
16,133
-23,181
-59% -$1.46M 0.79% 37
2016
Q3 		$2.5M Buy
39,314
+32,011
+438% +$2.35M 2.05% 20
2016
Q2 		$543K Sell
7,303
-736
-9% -$54.6K 0.49% 49
2016
Q1 		$537K Sell
8,039
-279
-3% -$17K 0.45% 54
2015
Q4 		$563K Sell
8,318
-758
-8% -$46.8K 0.41% 60
2015
Q3 		$485K Buy
+9,076
New +$551K 0.35% 75
2015
Q2 		– Sell
-94,739
Closed -$4.56M – 134
2015
Q1 		$4.56M Buy
94,739
+59,414
+168% +$2.28M 2.64% 8
2014
Q4 		$1.17M Sell
35,325
-549
-2% -$17.9K 0.73% 35
2014
Q3 		$1.05M Sell
35,874
-4,373
-11% -$145K 0.58% 43
2014
Q2 		$1.56M Sell
40,247
-1,022
-2% -$41.5K 0.8% 34
2014
Q1 		$1.73M Buy
41,269
+4,044
+11% +$169K 0.86% 35
2013
Q4 		$1.22M Buy
+37,225
New +$1.21M 0.66% 39

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

1492 Capital Management's LGND Position: Q1 2026 in Review

1492 Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 4.4% in Q1 2026, buying an estimated $16.2K and bringing the position to 1,958 shares worth $391K. The position accounts for 0.15% of the portfolio, ranked #91.

1492 Capital Management first reported a position in LGND in Q4 2013 and has held it in 25 quarters since. The position peaked at $4.56M in Q1 2015. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • 1492 Capital Management held 1,958 shares of Ligand Pharmaceuticals worth $391K as of Q1 2026.
  • 1492 Capital Management bought 82 Ligand Pharmaceuticals shares in Q1 2026, an estimated $16.2K.
  • Ligand Pharmaceuticals made up 0.15% of 1492 Capital Management's portfolio in Q1 2026, its #91 holding.
  • 1492 Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 25 quarters since.
  • 1492 Capital Management's Ligand Pharmaceuticals position peaked at $4.56M in Q1 2015.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.